Clinical Trials Logo

Bronchial Neoplasm Benign clinical trials

View clinical trials related to Bronchial Neoplasm Benign.

Filter by:
  • None
  • Page 1

NCT ID: NCT04413292 Completed - Clinical trials for Bronchial Neoplasm Benign

Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases

Start date: January 1, 2017
Phase:
Study type: Observational

Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis. Fibulin-3, a matrix glycoprotein, was recently presented as a promising novel biomarker for malignant pleural mesothelioma. The aim of this study was to validate the expression levels of survivin and fibulin-3 in benign and malignant respiratory diseases. Patients and methods: The study included 73 patients, with various benign and malignant respiratory diseases. For validation of the data, a control group including 20 healthy subjects was chosen. The clinical and radiological assessments of the included individuals were done. The serum survivin and fibulin-3 levels were measured using ELISA assays kits, while their local expressions in the lung and pleura were assessed using western blot analysis.